Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and tolerability of Mocertatug Rezetecan in adults with advanced solid tumors, including platinum-resistant ovarian cancer and endometrial cancer. The study aims to observe how levels of Mocertatug Rezetecan change over time at different doses. Participants have tumors that have not responded to or cannot tolerate standard treatments. The study includes two parts dose escalation and dose expansion, both involving administration of Mocertatug Rezetecan as an injection. Participants receive varying doses to determine safety, tolerability, and clinical activity. Tissue samples will be collected for biomarker analysis, including expression of B7-H4. The study may last up to approximately 31 months depending on the part and participant response. Participants will undergo regular assessments including evaluation of tumor response using standard criteria, monitoring of blood and urine tests, vital signs, ECGs, and other laboratory measures. Safety is closely monitored through tracking adverse events and specific toxicity markers. The main outcomes measured include dose limiting toxicities in the first 21 days and objective response rates over about 28 months. Follow-up evaluations continue for safety and clinical activity throughout the study.
Actively Recruiting
Researchers are evaluating a new combination treatment of Sigvotatug Vedotin plus pembrolizumab compared to pembrolizumab alone in people with non-small cell lung cancer NSCLC that has high levels of PD-L1 protein. This protein can limit the bodys immune response to cancer. The study focuses on participants with advanced NSCLC Stage 3 or 4 who have PD-L1 expression in over 50% of their cancer cells and who are eligible for pembrolizumab treatment. All participants will receive pembrolizumab through an intravenous infusion every six weeks at the study clinic. Half of the participants will also receive Sigvotatug Vedotin as an intravenous infusion every two weeks alongside pembrolizumab. Participants may continue pembrolizumab treatment for up to about two years, while those receiving Sigvotatug Vedotin can continue until their cancer no longer responds to treatment. During the study, participants will visit the clinic regularly for monitoring, including assessments of overall survival and progression-free survival over approximately two years. The research team will evaluate how well participants respond to treatment and monitor side effects. Additional laboratory tests will assess drug levels and immune responses. The total study participation may last up to four years, with ongoing evaluations to measure treatment effects and safety.